New Drugs and Clinical Research · us
Another Oral Option for Treatment-Refractory Herpes: FDA Approves pritelivir for Immunocompromised Adults
When commonly used antivirals fail to heal herpes lesions, immunocompromised patients often face more difficult treatment challenges. Newly approved pritelivir increased the proportion of patients achieving complete healing within 28 days in a randomized trial, but this advance has a clearly defined scope and does not mean the infection can be eradicated.
For immunocompromised people, herpes simplex may be more than a brief discomfort: painful lesions on the skin and mucous membranes can recur and may remain unhealed even after treatment. On October 9, the U.S. Food and Drug Administration (FDA) approved the oral drug Hovilpri (pritelivir), adding an option for these adult patients with limited treatment choices.
The approval covers skin and mucosal lesions caused by herpes simplex virus (HSV) in immunocompromised adults who have not responded to treatment with acyclovir, valacyclovir, or famciclovir. The FDA granted the application priority review; the approval does not cover everyone with a herpes infection.
The evidence supporting the approval came from Part C of the phase 3 PRIOH-1 trial. This randomized, open-label superiority trial enrolled 101 adults and compared pritelivir with alternative therapies selected by the study physicians. Participants’ underlying immunocompromising conditions included blood disorders or malignancies, hematopoietic stem cell and solid organ transplants, and HIV infection, reflecting the different clinical settings in which these treatment-refractory infections may occur.
By day 28, 63% of patients in the pritelivir group had achieved complete healing of all lesions, compared with 34% in the control group—a difference of 29 percentage points. This endpoint measures whether lesions have healed; it cannot establish that the virus has been cleared or that patients will not experience future recurrences. HSV can remain latent in the body after infection, and improvement in lesions and eradication of the infection are different things.
The treatment course also allowed for an extension: patients whose lesions had not completely healed by day 28 but continued to improve could receive treatment for up to 42 days. Contemporary OB/GYN, citing data previously released by the manufacturer AiCuris, reported that after extended treatment, the proportion achieving complete healing was 82.4%, compared with 42.0% in the control group. These figures come from a longer observation period and should be interpreted separately from the 28-day primary endpoint used in the FDA announcement.
On safety, the FDA identified headache as the most common adverse reaction and noted that the prescribing information lists specific drug interactions. Manufacturer data cited by the same publication also showed that 2% of patients in the pritelivir group discontinued treatment because of adverse events, compared with 20% in the control group. This difference offers an indication of tolerability but is insufficient to characterize medication risks for all patients.
The significance of this approval is that it provides another oral option for patients whose existing antiviral treatments have not worked. The limits of the evidence are also clear: the trial enrolled 101 people, used an open-label design, and included different therapies in the control group. Short-term lesion healing results still cannot fully answer questions about long-term recurrence, subsequent drug resistance, or differences in efficacy among various groups of immunocompromised patients.